(Q40180350)

English

Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells

scientific article published on 16 November 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

object named as

fowlpox virus

1 reference

based on heuristic

inferred from title

author name string

Antonia Radaelli

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Olivia Bonduelle

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Paola Beggio

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Brice Mahe

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Eleana Pozzi

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Veronica Elli

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Manuela Paganini

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Carlo Zanotto

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Carlo De Giuli Morghen

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Béhazine Combadière

10

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

16 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

2128-2138

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Potential use of non-replicating vectors as recombinant vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Recombinant fowlpox virus inducing protective immunity in non-avian species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Formation of Lentivirus Particles by Mammalian Cells Infected with Recombinant Fowlpox Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Production of Immunogenic HIV-1 Viruslike Particles in Stably Engineered Monkey Cell Lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Biochemical analysis of the N-glycosylation pathway in baculovirus-infected lepidopteran insect cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Production of non-infectious human immunodeficiency virus-like particles which package specifically viral RNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

DNA vaccines: a key for inducing long-term cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

The prime-boost strategy: exciting prospects for improved vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

Simian immunodeficiency virus DNA vaccine trial in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.009

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.11.009

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40180350&oldid=2098411272"